Rasburicase

Abstract

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The January 2003 monograph topics are ezetimibe, enfurvitide, aripiprazole, atomoxetine, and amoxicillin/clavulanate potassium extended-release tablets. The DUE is on ezetimibe.

Get full access to this article

View all access options for this article.

References

Elitek [package literature]. Sanofi Synthelabo Inc.; July 2002.

Anonymous. Fasturtec infusion. Pharm J. 2001; 266(7145): 601. (www.pharmj.com) Accessed September 19, 2001.

Pui

C-H

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia: The compassionate use experience [abstract 3106.]. American Society of Hematology, 42nd Annual Meeting; December 1–5, 2000; San Francisco, CA. www.hematology.org. Accessed October 26, 2001.

Pui

C.H.

Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001; 19: 697–704.

Committee for proprietary medicinal products European Public Assessment Report (EPAR): Fasturtec. European Agency for the Evaluation of Medicinal Products. 2001. (www.eudra.org/emea.html) Accessed November 6, 2001.

Pui

C.H.

Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia. 1997; 11: 1813–6.

Patte

European experience in the treatment of hyperuricemia. Semin Hematol. 2001; 38(suppl 10): 9–12.

Pui

C.H.

Urate oxidase in the prophylaxis or treatment of hyperuricemia: The United States experience. Semin Hematol. 2001; 38(suppl 10): 13–21.

Goldman

S.C.

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001; 97: 2998–3003.

10.

Goldman

Rasburicase is safe and effective in treatment and prophylaxis of hyperuricemia in children and adults with hematological malignancies at risk of tumor lysis syndrome [abstract]. 38th Annual Meeting of the American Society of Clinical Oncology; May 18–21, 2002; Orlando, FL. Abstract 1595.

11.

Pui

C.H.

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: Results of a compassionate-use trial. Leukemia. 2001; 15: 1505–9.

12.

Pui

C.H.

Recombinant urate oxidase (rasburicase) prevents uric acid accumulation during chemotherapy as evidenced by urinary allantoin excretion (abstract 1479). 38th Annual Meeting of the American Society of Clinical Oncology; May 18–21, 2002; Orlando, FL.

13.

van den Berg

Prevention of hyperuricemia with urate oxidase (rasburicase) in children during chemotherapy induction [abstract 473]. Blood. 2001; 98(11, pt. 1).

14.

Crews

K.R.

Methotrexate pharmacokinetics following hypouricemic treatment with allopurinol vs. urate oxidase in children with acute lymphoblastic leukemia (ALL) [abstract 474]. Blood. 2001; 98(11, pt. 1).